BiotechTube
VisionGate

VisionGate

Phoenix, United States· Est.
visiongate3d.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17.5M

Overview

VisionGate is a private, pre-revenue diagnostics company developing the LuCED® Lung Test, a non-invasive, AI-powered screening tool for early-stage lung cancer. Its patented Cell-CT™ platform creates high-resolution 3D images of cells from sputum samples, enabling highly accurate detection. Founded in 2007 and based in Phoenix, Arizona, the company is led by a seasoned team with deep experience in medical imaging and diagnostics, and it holds a significant intellectual property portfolio with 35 patents. VisionGate aims to address a critical unmet need in lung cancer screening, particularly for high-risk populations.

Oncology

Technology Platform

Cell-CT™ platform for high-resolution 3D cellular imaging combined with AI-powered analysis for detecting abnormal cells in cytological samples.

Funding History

3
Total raised:$17.5M
Grant$2.5M
Series B$10M
Series A$5M

Opportunities

The large, underserved market for convenient lung cancer screening in high-risk populations presents a major opportunity.
The Cell-CT™ platform's flexibility also offers potential for expansion into diagnosing other cancers from cytological samples.

Risk Factors

Key risks include regulatory hurdles for FDA approval, challenges in commercializing a novel diagnostic and securing insurance reimbursement, and competition from other early detection technologies like liquid biopsies.

Competitive Landscape

VisionGate competes in the early lung cancer detection space against low-dose CT scans (the current standard) and emerging liquid biopsy tests that detect circulating tumor DNA or other biomarkers. Its differentiation lies in its non-invasive sputum sample and unique 3D cellular imaging approach.

More companies in Diagnostics & Precision Medicine →More companies in United States →